Aicuris AG, of Wuppertal, Germany, and Merck & Co. Inc., of Whitehouse Station, N.J., said phase II results were published in the New England Journal of Medicine showing the safety and efficacy of letermovir, an oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant.